News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's COMP for Defibrotide for the Prevention of GvHD


10/11/2013 9:45:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

VILLA GUARDIA, Italy, Oct. 10, 2013 (GLOBE NEWSWIRE) -- Gentium S.p.A. (Nasdaq:GENT) (the "Company") announced today that the European Medicines Agency's Committee for Orphan Medicinal Products ("COMP") has issued a positive opinion on the Company's application for orphan medicinal product status for Defibrotide for the prevention of Graft versus Host Disease ("GvHD"). The positive opinion of the COMP has now been forwarded to the EU commission for final approval and publication in the EU community register.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES